Ductal Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Clinical Trials
• Forums

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Conditions:   Ductal Breast Carcinoma In Situ;   HER2/Neu Positive Interventions:   Biological: Granulocyte-Macrophage Colony-Stimulating Factor;   Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC;   Procedure: Therapeutic Conventional Surgery Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2019 Category: Research Source Type: clinical trials